Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2025 05:00 ET | Source: Osivax

Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate, OVX836

Phase 2b to assess efficacy, safety, and immunogenicity2,850 participants to be enrolled across European countries Lyon, France and Liège, Belgium – September 16, 2025 – Osivax, a biopharmaceutical...